PARTNERING
FOR DEVELOPMENT
AND DELIVERY
ACHIEVEMENTS 2010-2017
17
products licensed
to the MPP
130+
pharmaceutical
development projects
managed by MPP's
generic partners
20
generic manufacturers
and product developers
sublicensed from
the MPP
Vision, Mission,
Governance and
strategy
A world in which people in low- and middle-income countries have rapid access to affordable and appropriate HIV, hepatitis C and tuberculosis treatments.
hiv
An estimated 36.7 million people in the world were living with HIV in 2016 including more than two million children. By June 2017, 20.9 million people were receiving antiretroviral therapy.
Yet, 16 million people still lack access to HIV medicines. This is well below the 80% target proposed by UNAIDS. The dearth of preferred paediatric formulations also contributes to the limited progress in HIV treatment access in children.
Hepatitis C
Approximately 71 million people in the world have chronic hepatitis C infection. Antiviral medicines can cure more than 95% of patients. But access to diagnosis and treatment is low, and solutions – such as new direct-acting antivirals – are only now beginning to reach some people in low- and middle-income countries where the vast majority of people with the virus live. Almost 400,000 people die each year, mostly from cirrhosis and hepatocellular carcinoma.
Tuberculosis
In 2016, 1.7 million people in the world died of tuberculosis (TB) – a treatable and curable disease. More than 95% of these deaths occurred in low- and middle-income countries.
The dearth of new treatments to combat ultidrug-resistant TB (MDR-TB) is specifically threatening progress towards the United Nations Sustainable Development Goals’ targets to end the tuberculosis epidemic by 2030.
Product Development
& TECHNICAL EXPERTISE
With its generic partners, the MPP continued to support efforts to accelerate the development and delivery of generic versions of hepatitis C and HIV medicines in 2017.
FINANCIAL STATEMENTS
for the year ended December 31, 2017 and Report of the Statutory Auditor
